Does the FDA approve bepirovirsen for chronic hepatitis B?
Will the FDA approve GSK and Ionis's bepirovirsen New Drug Application for the treatment of adults with chronic hepatitis B by its October 26, 2026 PDUFA target action date?
Leans yes — Breakthrough Therapy Designation plus Priority Review plus a successful pivotal readout is a historically strong combination for first-cycle approval, though the modest absolute cure rates leave some room for a label fight or a short extension
The bull case: BTD plus Priority Review plus positive pivotal B-Well 1/2 data is a combination that historically clears the FDA on the first review cycle at a high rate, GSK and Ionis have a long track record of antisense-oligonucleotide approvals together, and sell-side analysts have raised price targets explicitly pricing in approval. The bear case: a 19-26% functional cure rate means most treated patients still don't hit the headline outcome, Ionis's own stock fell slightly on the readout day despite the 'positive' framing, and competitor Arbutus Biopharma's early-stage imdusiran has posted a higher 25-50% cure rate in its own small cohort — a reminder the FDA could still ask for more durability or safety data given the drug's modest standalone efficacy.
Resolves Oct 26, 2026 · PDUFA target action date for bepirovirsen's NDA
Pooled Phase 3 B-Well 1/2 data released in January 2026 showed bepirovirsen plus standard care achieved a 19% functional cure rate in patients with baseline HBsAg ≤3,000 IU/mL (26% in the ≤1,000 IU/mL subgroup) versus 0% on standard care alone, meeting the trials' primary endpoint. The FDA granted Breakthrough Therapy Designation and accepted the NDA for Priority Review in April 2026, setting the Oct 26 goal date; Morgan Stanley raised its Ionis price target to $130 from $95 on the data. If approved, it would be the first-in-class functional cure for chronic hepatitis B, a disease with no curative therapy on the market today. GSK's own stock barely moved on the priority-review news (-0.7%), a muted reaction some read as the market already pricing in a high approval probability.
The FDA either approves the NDA (with or without labeling conditions) by the goal date or it issues a Complete Response Letter or delays the decision — a discrete regulatory action tied to a published statutory deadline.
Researched Oct 6, 2026 · tracked since Oct 6, 2026
Build a position
You agree with the market.
Nothing here has positive expected value — the price already reflects this view. Move the slider to where you think the odds actually are.
Take a side
FDA approves bepirovirsenthis is “yes”
Breakthrough Therapy Designation, Priority Review, and positive pivotal B-Well 1/2 data are a combination that historically clears the FDA at a high rate on the first review cycle, consistent with trackers putting baseline approval odds near 85%.
Worth knowing: Functional cure rates of 19-26% mean most treated patients still don't achieve the headline outcome, and antisense drugs have a history of the FDA requesting extra safety or durability data close to the goal date — Priority Review shortens the typical timeline but doesn't guarantee the date holds without a three-month extension.
FDA delays or rejects bepirovirsen
Modest absolute cure rates, a muted investor reaction to the pivotal data itself, and a competitor posting a higher early-stage cure rate all leave room for the FDA to ask for more data rather than approve outright on this cycle.
Worth knowing: Breakthrough Therapy Designation plus Priority Review is a strong prior for approval — most NDAs that reach this regulatory stage with positive pivotal data are approved on the first cycle, so betting on rejection is betting against a favorable regulatory base rate.
7 sources, leaning both ways
- yesHCPLive — FDA Grants Bepirovirsen Breakthrough Therapy Designation, Priority Review for Chronic Hepatitis BConfirms BTD and Priority Review acceptance with an October 26, 2026 PDUFA goal date set off the positive B-Well 1/2 pivotal data.
- yesGSK — Bepirovirsen achieves unprecedented functional cure rates with potential to redefine treatment for chronic hepatitis BGSK's own press release detailing the 19%/26% functional cure rates versus 0% on standard care, the basis for the regulatory filing.
- mixedBioPharma Dive — GSK, Ionis claim study success for RNA-based hepatitis B drugIndependent trade-press read on the trial results, noting the cure rates are a meaningful clinical advance but still leave most patients without a functional cure.
- yesCoinCentral — Ionis Pharmaceuticals (IONS) Stock: FDA Review Progress and GSK Data Fuel RallyReports Morgan Stanley's price-target raise to $130 from $95 on Ionis following the bepirovirsen data and priority-review news.
- yesGoodRx — Upcoming FDA Approvals: New Drugs and Therapies That May Be Approved in 2026Lists bepirovirsen's Oct 26, 2026 PDUFA date with an estimated 85% approval probability, the baseline odds this topic's consensus is anchored to.
- noBiotechIQ Journal — Bepirovirsen Raises the Bar, but the Race Isn't OverHighlights Arbutus Biopharma's competing imdusiran posting a 25-50% functional cure rate in early Phase 2a data — evidence bepirovirsen's efficacy edge is narrower than the headline numbers suggest.
- mixedTradersUnion — GSK stock trades flat as bepirovirsen priority review by US FDA gives supportDocuments GSK shares actually slipping ~0.7% on the priority-review news, a muted reaction consistent with the market already pricing in a high approval probability rather than treating it as new information.